Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382182719> ?p ?o ?g. }
- W4382182719 endingPage "2135" @default.
- W4382182719 startingPage "2135" @default.
- W4382182719 abstract "Intravenous thrombolysis is increasingly used in patients with minor stroke, but its benefit in patients with minor nondisabling stroke is unknown.To investigate whether dual antiplatelet therapy (DAPT) is noninferior to intravenous thrombolysis among patients with minor nondisabling acute ischemic stroke.This multicenter, open-label, blinded end point, noninferiority randomized clinical trial included 760 patients with acute minor nondisabling stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤5, with ≤1 point on the NIHSS in several key single-item scores; scale range, 0-42). The trial was conducted at 38 hospitals in China from October 2018 through April 2022. The final follow-up was on July 18, 2022.Eligible patients were randomized within 4.5 hours of symptom onset to the DAPT group (n = 393), who received 300 mg of clopidogrel on the first day followed by 75 mg daily for 12 (±2) days, 100 mg of aspirin on the first day followed by 100 mg daily for 12 (±2) days, and guideline-based antiplatelet treatment until 90 days, or the alteplase group (n = 367), who received intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg) followed by guideline-based antiplatelet treatment beginning 24 hours after receipt of alteplase.The primary end point was excellent functional outcome, defined as a modified Rankin Scale score of 0 or 1 (range, 0-6), at 90 days. The noninferiority of DAPT to alteplase was defined on the basis of a lower boundary of the 1-sided 97.5% CI of the risk difference greater than or equal to -4.5% (noninferiority margin) based on a full analysis set, which included all randomized participants with at least 1 efficacy evaluation, regardless of treatment group. The 90-day end points were assessed in a blinded manner. A safety end point was symptomatic intracerebral hemorrhage up to 90 days.Among 760 eligible randomized patients (median [IQR] age, 64 [57-71] years; 223 [31.0%] women; median [IQR] NIHSS score, 2 [1-3]), 719 (94.6%) completed the trial. At 90 days, 93.8% of patients (346/369) in the DAPT group and 91.4% (320/350) in the alteplase group had an excellent functional outcome (risk difference, 2.3% [95% CI, -1.5% to 6.2%]; crude relative risk, 1.38 [95% CI, 0.81-2.32]). The unadjusted lower limit of the 1-sided 97.5% CI was -1.5%, which is larger than the -4.5% noninferiority margin (P for noninferiority <.001). Symptomatic intracerebral hemorrhage at 90 days occurred in 1 of 371 participants (0.3%) in the DAPT group and 3 of 351 (0.9%) in the alteplase group.Among patients with minor nondisabling acute ischemic stroke presenting within 4.5 hours of symptom onset, DAPT was noninferior to intravenous alteplase with regard to excellent functional outcome at 90 days.ClinicalTrials.gov Identifier: NCT03661411." @default.
- W4382182719 created "2023-06-28" @default.
- W4382182719 creator A5002948434 @default.
- W4382182719 creator A5003166126 @default.
- W4382182719 creator A5007937008 @default.
- W4382182719 creator A5009075433 @default.
- W4382182719 creator A5013592263 @default.
- W4382182719 creator A5019234018 @default.
- W4382182719 creator A5020937747 @default.
- W4382182719 creator A5024928163 @default.
- W4382182719 creator A5026487071 @default.
- W4382182719 creator A5026604505 @default.
- W4382182719 creator A5029310702 @default.
- W4382182719 creator A5038385200 @default.
- W4382182719 creator A5040807087 @default.
- W4382182719 creator A5042231089 @default.
- W4382182719 creator A5043893764 @default.
- W4382182719 creator A5051189159 @default.
- W4382182719 creator A5054361143 @default.
- W4382182719 creator A5059281058 @default.
- W4382182719 creator A5060595935 @default.
- W4382182719 creator A5061898583 @default.
- W4382182719 creator A5065990541 @default.
- W4382182719 creator A5066716873 @default.
- W4382182719 creator A5070578002 @default.
- W4382182719 creator A5075195203 @default.
- W4382182719 creator A5076683249 @default.
- W4382182719 creator A5078442427 @default.
- W4382182719 creator A5080176831 @default.
- W4382182719 creator A5081411724 @default.
- W4382182719 creator A5092274331 @default.
- W4382182719 creator A5052993607 @default.
- W4382182719 date "2023-06-27" @default.
- W4382182719 modified "2023-10-15" @default.
- W4382182719 title "Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke" @default.
- W4382182719 cites W1480729244 @default.
- W4382182719 cites W1553773467 @default.
- W4382182719 cites W2081615170 @default.
- W4382182719 cites W2153794230 @default.
- W4382182719 cites W2171165037 @default.
- W4382182719 cites W2203834727 @default.
- W4382182719 cites W2606030971 @default.
- W4382182719 cites W2791425992 @default.
- W4382182719 cites W2804570339 @default.
- W4382182719 cites W2870184972 @default.
- W4382182719 cites W2925819427 @default.
- W4382182719 cites W2982303713 @default.
- W4382182719 cites W3000383169 @default.
- W4382182719 cites W3000629658 @default.
- W4382182719 cites W3006155796 @default.
- W4382182719 cites W3006514501 @default.
- W4382182719 cites W3023622410 @default.
- W4382182719 cites W3036502738 @default.
- W4382182719 cites W3093124392 @default.
- W4382182719 cites W3094179140 @default.
- W4382182719 cites W3129930662 @default.
- W4382182719 cites W3132060044 @default.
- W4382182719 cites W3157630068 @default.
- W4382182719 cites W3209603791 @default.
- W4382182719 cites W4255683973 @default.
- W4382182719 doi "https://doi.org/10.1001/jama.2023.7827" @default.
- W4382182719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37367978" @default.
- W4382182719 hasPublicationYear "2023" @default.
- W4382182719 type Work @default.
- W4382182719 citedByCount "3" @default.
- W4382182719 countsByYear W43821827192023 @default.
- W4382182719 crossrefType "journal-article" @default.
- W4382182719 hasAuthorship W4382182719A5002948434 @default.
- W4382182719 hasAuthorship W4382182719A5003166126 @default.
- W4382182719 hasAuthorship W4382182719A5007937008 @default.
- W4382182719 hasAuthorship W4382182719A5009075433 @default.
- W4382182719 hasAuthorship W4382182719A5013592263 @default.
- W4382182719 hasAuthorship W4382182719A5019234018 @default.
- W4382182719 hasAuthorship W4382182719A5020937747 @default.
- W4382182719 hasAuthorship W4382182719A5024928163 @default.
- W4382182719 hasAuthorship W4382182719A5026487071 @default.
- W4382182719 hasAuthorship W4382182719A5026604505 @default.
- W4382182719 hasAuthorship W4382182719A5029310702 @default.
- W4382182719 hasAuthorship W4382182719A5038385200 @default.
- W4382182719 hasAuthorship W4382182719A5040807087 @default.
- W4382182719 hasAuthorship W4382182719A5042231089 @default.
- W4382182719 hasAuthorship W4382182719A5043893764 @default.
- W4382182719 hasAuthorship W4382182719A5051189159 @default.
- W4382182719 hasAuthorship W4382182719A5052993607 @default.
- W4382182719 hasAuthorship W4382182719A5054361143 @default.
- W4382182719 hasAuthorship W4382182719A5059281058 @default.
- W4382182719 hasAuthorship W4382182719A5060595935 @default.
- W4382182719 hasAuthorship W4382182719A5061898583 @default.
- W4382182719 hasAuthorship W4382182719A5065990541 @default.
- W4382182719 hasAuthorship W4382182719A5066716873 @default.
- W4382182719 hasAuthorship W4382182719A5070578002 @default.
- W4382182719 hasAuthorship W4382182719A5075195203 @default.
- W4382182719 hasAuthorship W4382182719A5076683249 @default.
- W4382182719 hasAuthorship W4382182719A5078442427 @default.
- W4382182719 hasAuthorship W4382182719A5080176831 @default.
- W4382182719 hasAuthorship W4382182719A5081411724 @default.
- W4382182719 hasAuthorship W4382182719A5092274331 @default.
- W4382182719 hasConcept C126322002 @default.